Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 10/20 | 0.51 |
| ▸ | MAOA | P21397 | 1/20 | 0.51 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.47 |
| ▸ | PPARA | Q07869 | 2/20 | 0.46 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.46 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.44 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4420232 | 0.85 | MAOB (0.51) | MAOBMAOANR4A2PPARAPARP10 | |
| SCHEMBL4419540 | 0.84 | MAOB (0.56) | MAOBMAOANR4A2PPARAFFAR1 | |
| SCHEMBL4418643 | 0.83 | MAOB (0.49) | MAOBMAOANR4A2PPARAPARP10 | |
| SCHEMBL4419046 | 0.81 | MAOB (0.60) | MAOBMAOAPARP10 | |
| SCHEMBL6447312 | 0.81 | MAOB (0.44) | MAOBMAOANR4A2PPARAPARP10 | |
| SCHEMBL4419043 | 0.81 | MAOB (0.60) | MAOBMAOAPARP10 | |
| SCHEMBL7153285 | 0.81 | MAOB (0.60) | MAOBMAOAPARP10 | |
| SCHEMBL5090748 | 0.81 | MAOB (0.63) | MAOBMAOANR4A2PARP10FFAR1 | |
| SCHEMBL13760599 | 0.78 | ALDH1A1 (0.51) | MAOBNR4A2 | |
| SCHEMBL6445857 | 0.78 | MAOB (0.61) | MAOBMAOANR4A2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1501804-A1 | ISOQUINOLINE DERIVATIVES MAO-B INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-02-02 | — | — | EP | disclosed |
| US-20030225122-A1 | 2-(S)-(6-(4-fluoro-benzyloxy)-3-oxo-3,4-dihydro-1H-isoquinolin -2-yl)- propionamide for example; Alzheimer's disease or senile dementia | HOFFMANN-LA ROCHE INC. | 2003-12-04 | — | — | US | disclosed |
| WO-2003091219-A1 | ISOQUINOLINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2003-11-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030225122-A1 | 2-(S)-(6-(4-fluoro-benzyloxy)-3-oxo-3,4-dihydro-1H-isoquinolin -2-yl)- propionamide for example; Alzheimer's disease or senile dementia | MAOB, MAOA, BACE2 | MAOB 1/4885MAOA 2/4885NR4A2 1590/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.